You are here

Merck

Analysts: Keytruda has a blockbuster market not factored into Merck’s forecasts—China

Fierce Pharma

Fri, 03/15/19 - 12:20 pm

immuno-oncology

Merck limits orders for bladder cancer drug as demand outstrips supply

Fierce Pharma

Thu, 03/14/19 - 11:48 am

Merck notches fourth lung cancer approval in Europe for flagship Keytruda

Endpoints

Thu, 03/14/19 - 10:14 am

metastatic squamous non-small cell lung cancer

Merck gives King's College London, Wellcome Trust up to $340M in deal to develop non-opioid painkillers

Endpoints

Sat, 03/9/19 - 12:06 pm

Kings College London

non-opioid pain treatments

Merck Gets CHMP Nod for Six-Week Dosing Option of Keytruda

Yahoo/Zacks.com

Tue, 03/5/19 - 09:35 am

AstraZeneca, Merck notch another major Lynparza trial win — this time in pancreatic cancer

Endpoints

Tue, 02/26/19 - 09:34 am

pancreatic cancer

clinical trials

BRCA-mutated prostate cancer

Biogen, BioMarin, Lilly and Bristol-Myers Could Be in Crosshairs of Acquirers

Yahoo/Guru Focus

Sun, 02/24/19 - 11:36 pm

Bristol-Myers Squibb

The fighter, the saint, and the odd man out: the executives who will defend pharma before Congress

Stat

Thu, 02/21/19 - 12:41 pm

Richard Gonzalez

Jennifer Taubert

Olivier Brandicourt

Giovanni Caforio

Bristol-Myers Squibb

Merck Gets Priority Review for Keytruda in Third-Line SCLC

Yahoo/Zacks.com

Thu, 02/21/19 - 10:11 am

Merck to buy immunotherapy developer Immune Design for $300 million

Reuters

Thu, 02/21/19 - 09:58 am

Pfizer, Merck, J&J well-positioned for M&A and Biogen and BioMarin are prime targets: report

Fierce Pharma

Wed, 02/20/19 - 11:59 am

Merck expands Mass. reach with Torque cancer collaboration

Bizjournals

Wed, 02/20/19 - 10:09 am

immuno-oncology

Keytruda gets okay from FDA for adjuvant melanoma

Pharmaforum

Wed, 02/20/19 - 09:49 am

adjuvant melanoma

Merck’s PhIII liver cancer study for Keytruda fails on two key endpoints, just three months after the FDA gave it the green light

Endpoints

Tue, 02/19/19 - 07:48 pm

clinical trials

Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster

Motley Fool

Tue, 02/19/19 - 12:20 pm

Layoffs Hit California Biopharma Companies

BioSpace

Mon, 02/18/19 - 11:49 am

Merck, Pfizer drug combo extends kidney cancer survival -study

Yahoo/Reuters

Sun, 02/17/19 - 11:57 pm

Keytruda-Inlyta combo under Priority Review for first-line RCC

BioCentury

Fri, 02/15/19 - 10:34 am

renal cell carcinoma

priority review

Merck plans trio of Phase 3 Keytruda studies in prostate cancer

BioPharma Dive

Thu, 02/14/19 - 05:56 pm

prostate cancer

clinical trials

Asco-GU – Bristol’s renal cancer lead looks to be short-lived

EP Vantage

Mon, 02/11/19 - 08:24 pm

renal cell carcinoma

Bristol-Myers Squibb

clinical trials

Pages